INmune Bio strikes warrant inducement deal, extends maturity on remaining warrants

INmune Bio Inc. entered into a warrant inducement agreement and a related amendment on June 30, 2026, involving holders of common stock purchase warrants originally issued in the company's April 2024 offerings. The agreement, called the Inducement Letter, and an amendment called the Second Amendment, covered warrants issued on April 24, 2024 and April 29, 2024, which had previously been amended on December 22, 2025.¹

Under the terms, the company offered holders the chance to exercise 50% of their April 2024 warrants at a reduced exercise price of $1.40 per share, down from $1.95, and agreed to extend the maturity date on the remaining unexercised half from June 30, 2026 to December 31, 2027.¹

Holders agreed to exercise 647,112 warrants for cash, representing half of their total holdings, and to purchase an equal number of shares at the reduced price in exchange for the maturity extension on the other half.¹ INmune Bio said it expects to receive approximately $905,957 from the exercise of these warrants.¹

The Second Amendment formally extended the maturity date for the unexercised 50% of the April 2024 warrants from June 30, 2026 to December 31, 2027.¹

Regarding the shares underlying the warrants, the issuance or resale of the common stock has been registered under an effective registration statement, File No. 333-279036.¹ That registration statement remains effective and will cover the issuance or resale of shares tied to the exercised portion of the warrants.¹

The filing noted that the summary provided does not purport to be complete and is qualified by reference to the full text of the Inducement Letter and Second Amendment, filed as exhibits to the 8-K.¹ The report was signed by CEO David Moss and dated July 1, 2026.